Introduction:
Epstein-Barr virus (EBV) is a gamma herpesvirus, which infects more than 90%
of the world population. It is closely associated with several types of malignancies, such as endemic Burkitt's lymphoma, Hodgkins lymphoma, nasal NK/T-cell lymphoma, nasopharyngeal carcinoma (NPC), and gastric carcinoma (GC). 1, 2 In these EBV-associated malignancies, the virus persists in tightly latent forms with restricted expression of viral latent proteins in every tumor cell. 1, 3 Reactivation of the latent virus into lytic cycle can lead to expression of over 70 viral proteins of higher immunogenicity and replication of viral genomes inside host cells. Despite the strong association with various cancers, current chemotherapy regimens ignore the EBV-positive status of the associated tumours due to difficulty in targeting the latent virus in these tumours.
Pharmacological reactivation of EBV lytic cycle to confer susceptibility to antiviral drugs is being explored as a potential therapeutic strategy against the EBV-associated diseases. 4 Studies have shown that a nucleoside-type antiviral drug ganciclovir (GCV) could be converted from an inactive form to cytotoxic form, when they are phosphorylated by the viral lytic protein kinase BGLF4. 5 The concept of this lytic induction therapy began in the treatment of EBV-positive lymphoma with combination of histone deacetylase (HDAC) inhibitors such as arginine butyrate or valproic acid (VPA) with GCV. 6 Feng et al. further showed that combination of chemotherapy and VPA could induce EBV lytic cycle and sensitize EBV-positive epithelial tumours to GCV treatment. 7 Recently, a clinical trial of the lytic induction therapy using combination of gemcitabine, VPA, and GCV was carried out in three NPC patients and demonstrated improved clinical outcomes. 8 Since the killing effect of GCV relies on expression of BGLF4, the efficacy of this treatment strategy greatly depends on the efficiency and specificity of lytic induction. The development of more and class IV HDACs (HDAC-11). [9] [10] [11] [12] HDAC inhibitors targeting different combinations of HDAC isoforms have been engaged into different stages of clinical trials for the treatment of cancers. 13 To date, two HDAC inhibitors, including suberoylanilide hydroxamic acid (SAHA) and romidepsin have been approved by the Food and Drug Agency (FDA) for treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma, respectively. 14, 15 Pan-HDAC inhibitors, which inhibit class I, II and IV HDAC isoforms, including trichostatin A, sodium butyrate, and VPA, are widely used to induce EBV lytic cycle in EBV-associated cancers in vitro. 7, 8, 16, 17 We have reported that pan-HDAC inhibitors such as SAHA can trigger the switch of EBV from latent to lytic cycle and mediate enhanced killing of EBV-positive epithelial cancer cells, including those of NPC and GC. 16, 17 However, the effect of several potentially more potent and selective HDAC inhibitors on EBV lytic cycle reactivation is still unknown.
In this study, we hypothesized that inhibition of one or several specific HDAC isoforms by selective HDAC inhibitors can potently induce EBV lytic cycle in EBV-positive NPC and GC cells. We investigated the effects of different selective HDAC inhibitors, which target different combinations of HDAC isoforms, for their abilities to induce EBV lytic cycle in EBV-positive NPC and GC cells. We also examined the potential mechanisms related to the EBV lytic reactivation and investigated the combinatorial effects of the specific HDAC inhibitors with ganciclovir on the killing of EBV-positive NPC and GC cells. EBV infected GC cell lines, respectively. 18 SNU-719 is a GC cell line containing native EBV genomes (purchased from the Korean Cell Line Bank). 19, 20 HONE1 and HA are paired EBV-negative and recombinant EBV infected NPC cell lines, respectively. 21, 22 C666-1 is an EBV-positive NPC cell line that harbors native EBV genomes. 23 AGS-BX1 and HONE1-EBV are generated by infecting AGS and HONE1 cells with recombinant EBV genomes expressing green fluorescent protein. 18, 21, 22 The cell lines were authenticated with an AmpF/STR Identifiler PCR Amplication Kit (Applied Biosystems, Foster City, CA), according to the manufacturer's protocol. The data were analyzed by GeneScan and GeneMapper TM ID Software (Applied Biosystems, Foster City, CA). The cells were cultured as previously described. 17, 24 G418 was added to maintain the recombinant EBV in AGS-BDneo, AGS-BX1, HA and HONE1-EBV cells in culture flasks. To avoid any unexpected interaction between G418 and drugs, G418 was not added during drug treatment.
Chemicals
The selective HDAC inhibitors including romidepsin, apicidin, MS-275, droxinostat and PCI34051 were purchased from Selleck (Selleck Chemicals, Houston, TX);
CAY10603 and SAHA were purchased from Cayman (Cayman Chemicals, Ann
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Western blot analysis
To analyze the expression of EBV lytic proteins, NPC and GC cells were treated with various concentrations of selective HDAC inhibitors for 48 hr. After treatment, the cells were pelleted and washed once with PBS. Proteins from the cell pellets were extracted and western blot analyses were performed as described previously. 16 EBV latent and lytic proteins were detected with anti-EBNA1, anti-Zta, anti-Rta, anti-BMRF1, anti-VCA p18, and anti-gp350/220 antibodies; cell cycle regulatory proteins, were detected with anti-p21
and anti-p-Rb antibodies; histone acetylation was detected with an anti-acetyl-H3 and anti-acetyl-H4 antibodies; apoptosis was detected with anti-PARP rabbit polyclonal antibody as described previously. 16 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Cell viability studies
EBV-negative and -positive NPC and GC cells were seeded in 24-well cell culture plates. Cells grown to 70% confluence were treated with combinations of various concentrations of romidepsin and GCV for 7 days. Cell viability was determined by trypan blue exclusion assay. 
Quantitative PCR assay

EBV infection assay
To examine the production of infectious viral particles, AGS-BX1 and HONE1-EBV cells, which were infected with GFP-expressing recombinant EBV, were treated with romidepsin with or without GCV for 5 days. The culture supernatants were collected and EBV infection assay was performed as previously described.
16
Knockdown constructs for HDACs
A pLKO TRC cloning vector (Addgene no. 10878) mammalian expression lentiviral plasmid was used to establish the HDAC-1, -2, and -3 knockdown constructs. For each HDAC, two sets of oligonucleotides were utilized to perform knockdown experiments.
The knockdown constructs were designed according to the information of the Public TRC portal: HDAC-1 (TRCN0000195672 and TRCN0000004816), HDAC-2 (TRCN0000195547 and TRCN0000196590), and HDAC-3 (TRCN0000004825 and TRCN0000196267). The scramble vector (Addgene 1864) served as a control.
Statistical analysis
In vitro experiments were performed in triplicate and repeated at least 3 times. Data were analyzed for statistical significance using One-way ANOVA Dunnett's Multiple
Comparison Test. P value < 0.05 was considered statistically significant. All statistical which was previously recognized as a pan-HDAC inhibitor, is selective against several HDAC isoforms, including HDAC-1, -2, -3, -6 and -8. 26 We, therefore, set out 
Romidepsin induced EBV lytic cycle and suppressed growth of EBV-positive NPC and GC xenografts in nude mice
We examined the in vivo effects of romidepsin on NPC and GC cells. HA and 
Romidepsin induced acetylation of histone H3 and up-regulation of p21 prior to the reactivation of EBV lytic cycle
Romidepsin is a class I HDAC inhibitor, which can selectively inhibit HDAC-1, -2 and -3 isoforms. 27 , 28 Acetylation of histone H3 and up-regulation of p21 WAF1 are two well-known markers following inhibition of HDAC-1, -2 or -3. [29] [30] [31] We compared the kinetics of expression of these two markers with those of EBV lytic proteins upon treatment with romidepsin by western blotting (Fig. 3a) . Expression of EBV immediate-early lytic protein (Zta) and early lytic protein (BMRF1) was first detected 12 hr post-treatment in AGS-BDneo cells and at 24 hr in HA cells. Expression of EBV late lytic protein, gp350/220, was clearly detected in HA cells at 48 hr post-treatment, whilst that in AGS-BDneo was only barely detected. Interestingly, both acetylation of histone H3 and up-regulation of p21 WAF1 were observed prior to the expression of Zta. The up-regulation of p21 WAF1 , which is a cyclin-dependent kinase inhibitor, led to down-regulation of several cell cycle regulatory proteins (cyclin B1, p-cdc2, cyclin D1 and p-Rb) and subsequent cell cycle arrest at G2/M phase in both HA and AGS-BDneo cells (Fig. 3b) . Collectively, our data suggest that the effects of HDAC inhibition, including histone acetylation and p21 WAF1 up-regulation, could be observed prior to the reactivation of EBV lytic cycle.
Induction of EBV lytic cycle was abrogated by a specific inhibitor of PKC-δ δ δ δ but not the inhibitors of PI3K, MEK, p38 MAPK, JNK or ATM pathways
We attempted to further characterize the mechanisms of EBV lytic cycle reactivation by romidepsin. Various reports showed that the phosphatidylinositol including Zta and Rta, in the HA and AGS-BDneo cells were examined by western blot analysis. Only rottlerin, but not other pathway blockers, was able to inhibit the expression of EBV lytic proteins, indicating that PKC-δ, rather than the PI3K, MEK, JNK, and p38 MAPK pathways, was required for EBV lytic cycle reactivation by romidepsin. We further found that rottlerin could suppress the expression of early lytic protein BMRF1 and up-regulation of p21 WAF1 (Fig. 4c ). In the same experiment, 
Romidepsin dose-dependently induced co-expression of EBV lytic protein and cell death marker in both NPC and GC cells
We have previously reported that induction of EBV lytic cycle by HDAC inhibitors could mediate enhanced killing of EBV-positive NPC and GC cells. 16, 17 Here, we investigated the co-expression of cleaved caspase-3 and EBV lytic protein in the HA and GC cells upon treatment with increasing concentrations of romidepsin for 5 days by flow cytometry. We found that romidepsin could dose-dependently induce the co-expression of EBV lytic proteins (Zta, BMRF1, and gp350/220) in both HA and AGS-BDneo cells. At 2.5 and 5 nM romidepsin, the percentages of AGS-BDneo and HA cells co-expressing cleaved caspase-3 and Zta were 50.9% and 24.4%, respectively ( Fig. 5a and 5b) . The data indicated that the majority of cells expressing EBV lytic proteins were undergoing apoptosis. Upon the same treatment, there were showed similar results to those of caspase-3 and lytic protein's co-staining ( Fig. 5c and 5d). When we compared the effect of romidepsin with another FDA-approved HDAC inhibitor SAHA, we found that romidepsin can induce similar percentages of cells to co-express EBV lytic protein and cleaved caspase-3 at a 2000-fold lower concentration (Fig. 5e ). These data suggest the potential application of romidepsin for the treatment of EBV-associated cancers.
Inhibition of HDAC-1, -2, or -3 by romidepsin conferred susceptibility of EBV-positive epithelial malignancies to ganciclovir treatment
Studies have shown that induction of EBV lytic cycle could confer susceptibility of EBV-associated cancer to treatment with ganciclovir. 5, 6, 8, 38 In this study, we also investigated the effect of combination of romidepsin and ganciclovir on the killing of EBV-negative and EBV-positive NPC and GC cells ( Fig. 6a and 6b ). According to our data, treatment with romidepsin alone was sufficient to induce enhanced killing of EBV-positive HA and AGS-BDneo cells, when compared with their EBV-negative counterparts. Interestingly, romidepsin could also confer susceptibility of the EBV-positive epithelial cells to the treatment with ganciclovir. Of note, the concentrations of romidepsin, which induced the expression of EBV lytic proteins without causing substantial cell death (refer to Fig. 5a and 5b), could mediate the most significant combinatorial killing effects with ganciclovir. We also analyzed the viral DNA replication and infectious virus production by quantitative PCR and EBV infection assays, respectively. Our data showed that treatment with ganciclovir could Fig. 6c and 6d) . The weak virion production in AGS-BX1 cells corresponds to the relatively weak expression level of EBV late lytic protein upon treatment with 2.5 nM romidepsin (refer to Fig. 5a ). We also tested the anti-tumor effects of combination of romidepsin and GCV on different EBV-negative and -positive xenografts in nude mice (Fig. 6e) . Our data showed that combination of romidepsin and GCV, when compared with either drug alone, mediated enhanced growth suppression of EBV-positive xenografts (HA, C666-1 and SNU-719).
However, such enhanced growth suppression by combination of romidepsin and GCV could not be observed in EBV-negative xenografts (HONE1). To assess the toxicity of the drug combination, we measured the weight of mice throughout the period of drug treatment and observed no significant weight loss in the mice treated with combination of romidepsin and GCV or either drug alone (Fig. 6f) . To investigate whether the enhanced killing by combination of romidepsin and GCV is related to inhibition of HDAC-1, -2 or -3, we performed short hairpin RNA (shRNA) knockdown experiments to individually knockdown either HDAC-1, -2 or -3 and analyzed the reactivation of EBV lytic cycle and susceptibility of EBV-positive cells to GCV (Fig. 6g and 6h) . We found that knockdown of either HDAC-1, -2 or -3 could be sufficient to induce the expression of Zta in HA cells. Our data also showed that Pharmacological reactivation of EBV into lytic cycle from its latency is being explored as a potential therapeutic strategy against the EBV-associated diseases. [4] [5] [6] [7] [8] Pan-HDAC inhibitors, which inhibit eleven HDAC isoforms, are widely used to induce EBV lytic cycle in EBV-associated cancer cells in vitro and in clinical trials. [4] [5] [6] [7] [8] We have also reported that pan-HDAC inhibitors including trichostatin A, VPA, sodium butyrate, and SAHA, could induce EBV lytic cycle in EBV-positive epithelial malignancies, including NPC and GC, and mediate enhanced cell death. 16, 17 Newly synthesized selective HDAC inhibitors, which target different combinations of specific HDAC isoforms, were reported to have more potent effects than pan-HDAC inhibitors against different types of cancers. 27, 28 In this study, we hypothesized that inhibition of one or several specific HDAC isoforms by selective HDAC inhibitors could more potently induce EBV lytic cycle in EBV-positive NPC and GC cells.
Among the selective HDAC inhibitors we have tested, romidepsin, which is FDA-approved for the treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma, 15 was found to be the most potent lytic cycle inducer. It could activate early phase of EBV lytic cycle at ~0.5 to 5 nM. These concentrations are much lower than the clinically achievable concentration in patients' plasma, which is around 800
nM. 28 We further tested the effect of romidepsin in vivo and found that romidepsin could also significantly induce EBV lytic cycle and suppress the growth of NPC and GC xenografts in nude mice. All these preclinical data suggest the potential application of romidepsin for the treatment of EBV-associated cancers such as NPC and GC.
Although HDAC inhibitors have been widely used to induce EBV lytic cycle in various types of cancer cells, the essential role of HDAC inhibition in the regulation of EBV lytic cycle reactivation is still unknown. According to our data, only the reactivate EBV lytic cycle in NPC cells. 39 The exact relationship of cell cycle arrest and lytic cycle reactivation in EBV-positive cancer cells deserves further investigation.
HDAC inhibitors targeting HDAC-1, -2 and -3 (romidepsin, MS-275 or apicidin)
To further evaluate the role of HDAC inhibition in the lytic reactivation by HDAC inhibitors, we performed shRNA knockdown experiments to specifically inhibit HDAC-1, -2 and -3. Interestingly, we found that inhibition of either HDAC-1, -2 or -3 was sufficient to induce EBV lytic cycle in the EBV-positive epithelial malignancies.
The data is consistent with the reported finding that overexpression of HDAC-2 could suppress the lytic cycle reactivation in NPC cells by HDAC inhibitors. 35 We also 
16, 40
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